No Data
Can Novo, Lilly Take Credit for U.S. Obesity Rate Decline?
Trending Stocks This Week as Strong Jobs Report Underscore Resilience of U.S. Economy
Weight-Loss Drugs Are Everywhere. How the GLP-1 Copycats Took Over. -- Barron's
The Trader: ResMed Stock Is Surging. Expect More Gains for the Medical Equipment Maker. -- Barron's
Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
What End of Eli Lilly's Weight-loss Drug Shortage Means for the Competition
No Data
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
105251507 : how much u short bro?
MonkeyGee OP 105251507 : has nothing to do with shorting or long. read LLY financial, how do it justify that price? it's like I charge you 80 dollars for a slice of pizza.
105251507 MonkeyGee OP : I know..I just want know if u short this stock that all..
selcitset 105251507 : its obv hes shorting lol
MonkeyGee OP 105251507 : okay, would you rather I say that LLY sales for fat drugs will continue to explode. Demand is so high that manufacturing can barely keep up. You will miss out if you don't buy now since it's mere 152X of current earnings. which is not significant since there are NVDA that has a much higher PE.
View more comments...